On Jun. 20, 2024, the U.S. Food and Drug Administration expanded the approval of Sarepta Therapeutics’ Elevidys (delandistrogene…
On Jun. 22, 2023, the U.S. Food and Drug Administration (FDA) approved Sarepta Therapeutics’s Elevidys, the first gene…
On Apr. 15. 2021, a team of researchers led by the University of Minnesota Medical School announced they…
On Feb. 25, 2021, the FDA granted approval to Sarepta Therapeutics for Amondys 45 (casimersen) injection for the…
On Aug. 12, 2020, the FDA granted accelerated approval to NS Pharma’s Viltepso (viltolarsen) injection for the treatment…
On Oct. 7, 2019, Penn Medicine announced it had developed gene therapy to treat Duchenne muscular dystrophy (DMD)…
In 2000, the Capillary electrophoresis DNA sequencer device was developed by Dr. Edward Yeung at Iowa State University….
In 1987, Boston Children’s Hospital researcher Lous Kunkel and his colleagues discovered the gene that causes Duchenne muscular…
In 1980, Sarepta Therapeutics was founded originally as AVI BioPharma. Today, Sarepta is on an urgent mission: engineer…